Drug Safety Information for LUMIGAN (Bimatoprost)
Safety-related Labeling Changes for LUMIGAN (BIMATOPROST) Rx Drug: FDA Link
Adverse Drug Reactions for LUMIGAN* (Bimatoprost)
These charts and graphs are based on reports received through the FDA Adverse Event Reporting System (FAERS) program (see below).
Top 20 Adverse Effects Associated with LUMIGAN
(reported in FDA Medwatch/FAERS Reports)
Side Effect | # of FDA Reports | |
---|---|---|
1 | Drug ineffective | 1469 |
2 | Ocular hyperaemia | 1183 |
3 | Madarosis | 1058 |
4 | Wrong technique in drug usage process | 807 |
5 | Eye irritation | 786 |
6 | Eye pruritus | 742 |
7 | Erythema of eyelid | 723 |
8 | Inappropriate schedule of drug administration | 474 |
9 | Eyelids pruritus | 451 |
10 | Incorrect dose administered | 437 |
11 | Eyelid oedema | 434 |
12 | Vision blurred | 400 |
13 | Trichorrhexis | 387 |
14 | Skin hyperpigmentation | 378 |
15 | Eye pain* | 353 |
16 | Erythema | 314 |
17 | Dry eye* | 279 |
18 | Headache | 275 |
19 | Eye swelling | 271 |
20 | Therapeutic response decreased | 255 |
* This side effect also appears in "Top 10 Side Effects of LUMIGAN " in the drug's Review Summary based on AskaPatient reviews.
Top 10 Reasons for Taking LUMIGAN
(associated with FDA Medwatch/FAERS Reports)
Reason | # of FDA Reports | |
---|---|---|
1 | Growth of eyelashes | 10201 |
2 | Glaucoma* | 4666 |
3 | Product used for unknown indication | 4347 |
4 | Hypotrichosis | 913 |
5 | Intraocular pressure increased | 618 |
6 | Open angle glaucoma | 234 |
7 | Hair growth abnormal | 226 |
8 | Madarosis | 225 |
9 | Intraocular pressure test | 106 |
10 | Eye disorder | 86 |
*Also a top-10 reason in AskaPatient Review Summary.
Types of Adverse Events for LUMIGAN
Total Reports Filed with FDA: 32251
Number of FDA Adverse Event Reports by Patient Age for LUMIGAN
Total Reports Filed with FDA: 32251*
* Reports for drugs with the same active ingredients have been aggregated in this analysis: Bimatoprost (Latisse, Lumigan, Bimatoprost)
Charts are based on 32251 reports filed with the FDA between 2004 and June 2015.
Adverse Event Reports are submitted to the FDA by pharmaceutical companies (mandatory reporting is required by manufacturers, distributors, or importers), health care providers such as doctors (voluntary reporting), and by patients themselves (voluntary reporting). More Information on FDA MedWatch (FDA Safety Information and Adverse Event Reporting Program)Voluntary reporting takes place under the FDA's MedWatch program, where health care professionals and consumers submit reports to FDA when they find a problem with a drug, medical device, biologic, or other FDA-regulated product. An adverse event is any undesirable experience or extreme side effect associated with the use of a medical product. Adverse events include: death, life threatening event, hospitalization, disability or permanent damage, congenital anomaly or birth defect, medical product use requiring a surgical or other intervention, or other serious medical situation believed to be caused by the drug.
Click to go back to search results and LUMIGAN Reviews and Review Summary .
Historical Analytics of FDA Adverse Event Reports Provided by Druginformer.com. FDA Drug Safety Information, including safety-related labeling updates, required post-approval safety studies, risk evaluation management strategies (REMS), alerts, and recalls are compiled by AskaPatient.com from the U.S. Food and Drug Administration.